Physician profile
Douglas E Mazzuca
NPI 1720348931
$2,464.59
in general payments reported to CMS, 2019-2025
13 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $79.58 · 2021: $73.42 · 2022: $297 · 2023: $302 · 2024: $618 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,588.57 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $165.48 | 2024-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Allergan, INC. | $142.60 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $134.85 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $105.13 | 2024-2025 | Xdemvy |
| Abbvie INC. | $96.82 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $62.53 | 2023-2025 | Vyzulta, Scoutpro Osmolarity System, Xiidra |
| Oyster Point Pharma, INC. | $53.34 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $48.95 | 2022-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $26.20 | 2022 | |
| Harrow Eye, LLC | $14.18 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $13.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mazzuca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.